two new cholesterol-lowering drugs, Kynamro (kye-NAM-roe, mipomersen) and Juxtapid (JUKS-tuh-pid, lomitapide)

April 2013

You'll hear about two new cholesterol-lowering drugs, Kynamro (kye-NAM-roe, mipomersen) and Juxtapid (JUKS-tuh-pid, lomitapide).

But they're NOT for the vast majority of lipid patients.

They're for patients with homozygous familial hypercholesterolemia...which occurs in about one in 1,000,000 people.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote